Starling Oncology, Inc.

Starling Oncology, Inc. (ticker: TOI), formerly known as The Oncology Institute, Inc., is a value-based, community-based oncology care provider operating in the healthcare sector. The company entered the public markets in 2021 through a de-SPAC merger with GX Acquisition Corp. II, a blank-check vehicle sponsored by GX Sponsor II LLC. Filing under its current corporate name, the company submitted an 8-K to the Securities and Exchange Commission on August 6, 2026, maintaining its public reporting obligations following a period of significant corporate change since its original SPAC transaction closed. To access full filing histories, sponsor profiles, and SPAC analytics for TOI and thousands of other transactions, sign up for SpacDesk.